Detalhe da pesquisa
1.
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med
; 377(19): 1813-1823, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891408
2.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(5): 701-710, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928620
3.
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Br J Clin Pharmacol
; 84(4): 764-775, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29243287
4.
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Lancet Oncol
; 18(10): 1307-1316, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28919011
5.
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Lancet Oncol
; 18(7): 863-873, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592387
6.
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Lancet Oncol
; 17(7): 984-993, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27283860
7.
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 17(5): 642-50, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27080216
8.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Lancet
; 386(9992): 444-51, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26037941
9.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Lancet Oncol
; 16(13): 1389-98, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26433819
10.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Cancer
; 120(4): 513-20, 2014 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24258498
11.
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Lung Cancer
; 189: 107451, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354535
12.
A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing.
Blood
; 118(17): 4732-9, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21868572
13.
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
Invest New Drugs
; 31(5): 1345-54, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23801303
14.
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Eur J Cancer
; 125: 114-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31864178
15.
Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease.
Biol Blood Marrow Transplant
; 15(12): 1609-19, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19744572
16.
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Nat Med
; 25(8): 1319, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267021
17.
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Nat Med
; 25(6): 936-940, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171879
18.
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Eur J Cancer
; 109: 61-69, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30690294
19.
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Nat Med
; 25(6): 941-946, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171878
20.
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
J Clin Oncol
; 36(1): 7-13, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29072975